301 related articles for article (PubMed ID: 16166198)
21. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis.
Hunter SG; Zhuang G; Brantley-Sieders D; Swat W; Cowan CW; Chen J
Mol Cell Biol; 2006 Jul; 26(13):4830-42. PubMed ID: 16782872
[TBL] [Abstract][Full Text] [Related]
22. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis.
Nakamoto M; Bergemann AD
Microsc Res Tech; 2002 Oct; 59(1):58-67. PubMed ID: 12242697
[TBL] [Abstract][Full Text] [Related]
23. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis.
Yoon WH; Jung YJ; Kim TD; Li G; Park BJ; Kim JY; Lee YC; Kim JM; Park JI; Park HD; No ZS; Lim K; Hwang BD; Kim YS
Clin Cancer Res; 2004 Jul; 10(13):4517-26. PubMed ID: 15240544
[TBL] [Abstract][Full Text] [Related]
24. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase.
Fang WB; Brantley-Sieders DM; Hwang Y; Ham AJ; Chen J
J Biol Chem; 2008 Jun; 283(23):16017-26. PubMed ID: 18387945
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
26. Differential EphA2 epitope display on normal versus malignant cells.
Coffman KT; Hu M; Carles-Kinch K; Tice D; Donacki N; Munyon K; Kifle G; Woods R; Langermann S; Kiener PA; Kinch MS
Cancer Res; 2003 Nov; 63(22):7907-12. PubMed ID: 14633720
[TBL] [Abstract][Full Text] [Related]
27. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix.
Eckhardt BL; Parker BS; van Laar RK; Restall CM; Natoli AL; Tavaria MD; Stanley KL; Sloan EK; Moseley JM; Anderson RL
Mol Cancer Res; 2005 Jan; 3(1):1-13. PubMed ID: 15671244
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases.
Baldwin C; Chen ZW; Bedirian A; Yokota N; Nasr SH; Rabb H; Lemay S
Am J Physiol Renal Physiol; 2006 Nov; 291(5):F960-71. PubMed ID: 16735461
[TBL] [Abstract][Full Text] [Related]
29. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
31. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.
Carles-Kinch K; Kilpatrick KE; Stewart JC; Kinch MS
Cancer Res; 2002 May; 62(10):2840-7. PubMed ID: 12019162
[TBL] [Abstract][Full Text] [Related]
32. Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis.
Carson-Walter EB; Hampton J; Shue E; Geynisman DM; Pillai PK; Sathanoori R; Madden SL; Hamilton RL; Walter KA
Clin Cancer Res; 2005 Nov; 11(21):7643-50. PubMed ID: 16278383
[TBL] [Abstract][Full Text] [Related]
33. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
[TBL] [Abstract][Full Text] [Related]
34. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style.
Parri M; Taddei ML; Bianchini F; Calorini L; Chiarugi P
Cancer Res; 2009 Mar; 69(5):2072-81. PubMed ID: 19244130
[TBL] [Abstract][Full Text] [Related]
35. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
36. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo.
Gershenwald JE; Sumner W; Calderone T; Wang Z; Huang S; Bar-Eli M
Oncogene; 2001 Jun; 20(26):3363-75. PubMed ID: 11423987
[TBL] [Abstract][Full Text] [Related]
37. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma.
Bello L; Lucini V; Costa F; Pluderi M; Giussani C; Acerbi F; Carrabba G; Pannacci M; Caronzolo D; Grosso S; Shinkaruk S; Colleoni F; Canron X; Tomei G; Deleris G; Bikfalvi A
Clin Cancer Res; 2004 Jul; 10(13):4527-37. PubMed ID: 15240545
[TBL] [Abstract][Full Text] [Related]
38. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
39. Exosomal EPHA2 derived from highly metastatic breast cancer cells promotes angiogenesis by activating the AMPK signaling pathway through Ephrin A1-EPHA2 forward signaling.
Han B; Zhang H; Tian R; Liu H; Wang Z; Wang Z; Tian J; Cui Y; Ren S; Zuo X; Tian R; Niu R; Zhang F
Theranostics; 2022; 12(9):4127-4146. PubMed ID: 35673569
[No Abstract] [Full Text] [Related]
40. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.
Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Hååg P; Viktorsson K
Oncotarget; 2016 Sep; 7(37):60332-60347. PubMed ID: 27533087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
